The first phase 3 trials are due to start in the first half of next year, using devices manufactured at GSK’s facility in Evreux, France. “If successful, this could lead to regulatory ...

April 15 (Reuters) - British pharmaceutical giant GSK (GSK.L), opens new tab has not met required ethical and regulatory standards in the marketing and prescription information for its Omjjara ...

GSK said that IDRX-42 addresses all the key KIT ... has expanded its rare disease portfolio with the acquisition of France's Theravia for an undisclosed sum. The importance of biosimilars only ...